ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

VLG Venture Life Group Plc

36.75
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 36.75 36.00 37.50 36.75 36.75 36.75 71,557 08:00:23
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Misc Retail Stores, Nec 43.98M 520k 0.0041 89.63 46.24M

Venture Life Group PLC Appointment of Chief Financial Officer (6279X)

01/05/2019 7:01am

UK Regulatory


Venture Life (LSE:VLG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Venture Life Charts.

TIDMVLG

RNS Number : 6279X

Venture Life Group PLC

01 May 2019

1 May 2019

Venture Life Group plc

("Venture Life" or the "Group")

Appointment of Chief Financial Officer

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, today announces that it has appointed Andrew Waters, FCA, to the Board of Venture Life as Chief Financial Officer with immediate effect.

Andrew has been working closely with the Board since February 2019 after the departure of former CFO, Adrian Crockett, earlier this year. Andrew is a Chartered Accountant having previously worked at PWC and then GlaxoSmithKline plc, where he spent 16 years in various financial and business management positions. Following this, Andrew co-founded two businesses, Cubase Consulting Ltd and Infirst Healthcare Ltd, which he led through three successful funding rounds, raising in excess of GBP40 million from private equity.

Dr Lynn Drummond, Chair of Venture Life, said: "We are delighted to welcome Andrew to the Board of Venture Life. Andrew brings a range of skills to the team to support the ambitious plans we have for the business over the coming years. I am confident Andrew will be a valuable and complementary addition to the executive team."

Disclosures required by Schedule 2(g) of the AIM Rules for Companies

In the past 5 years, Mark Andrew Waters, aged 52, has held the following positions where he was acting in the capacity of a Director:

 
 Current Directorships: 
 Cubase Consulting Ltd 
 AW Chartered Accountant 
 
 Past Directorships: 
 Infirst Healthcare Ltd 
 Infirst Healthcare Inc (USA) 
 Infirst Healthcare Ltd (Ireland) (formerly Immunocopea Ltd) 
 Respicopea Holding Ltd 
 

Andrew Waters does not have any interest in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

 
 Venture Life Group PLC                               +44(0) 1344 578004 
 Jerry Randall, Chief Executive Officer 
 
                                                      +44(0)20 7397 
 Cenkos Securities Ltd (Nomad and Broker)              8900 
 Mark Connelly / Stephen Keys / Cameron MacRitchie 
  (Corporate Finance) 
 Russell Kerr / Michael Johnson (Sales) 
 
                                                           +44(0)20 3405 
 Alma PR                                                    0208 
 Rebecca Sanders-Hewett / Hilary Buchanan / Helena 
  Bogle / Jessica Joynson 
 
 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAZMGFDKGVGLZM

(END) Dow Jones Newswires

May 01, 2019 02:01 ET (06:01 GMT)

1 Year Venture Life Chart

1 Year Venture Life Chart

1 Month Venture Life Chart

1 Month Venture Life Chart

Your Recent History

Delayed Upgrade Clock